Radiopharm Theranostics Radiopharm Theranostics (ASX:RAD) has the ambition to become a recognised leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. Our patients come first We believe in the power of disruptive innovation We are science and data driven We emphasise teamwork – two heads are better than one We value relationships which are honest, collaborative, mutually respectful and which result in a win-win for all When we fail, we don’t lose the lesson We believe in fair play Our partnerships with our physicians, researchers and medical institutions are essential to our success We strive to create a culture of integrity, that is inclusive, and a fun place to work We will aim to protect and enhance our investors’ capital
Radiopharm Theranostics - Half Yearly Report and Accounts 29/02/2024 14:42:00 To view the report, download the attached PDF.
Radiopharm Theranostics - Dosing begins in Phase 1 Pancreatic Imaging Study of RAD 301 29/02/2024 09:20:00 -- First Pancreatic Cancer participant dosed at the Montefiore Medical Center, New York, USA -- Phase I study of 9 participants is designed to assess the safety and dosimetry of RAD 301 -- A total…
Radiopharm Theranostics - Pilot Study Validates RAD Terbium-161 Radiotherapeutics 28/02/2024 09:52:00 -- Publication of first head-to-head data shows superior Therapeutic Index with Tb161 vs Lu177 in 6 metastatic castration-resistant prostate cancer patients. -- This Pilot study validates Radiophar…
Market Reports / by Melissa Darmawan - 2 years ago Tech lags on growth fears, energy rally continues: ASX falls 0.5% at noon 06 Jun 2022 - The Australian sharemarket has retreated this morning after three weeks of gains ahead of the Reserve Bank of Australia policy meeting tomorrow.
Interviews / by Lauren Evans - 2 years ago Radiopharm Theranostics (ASX:RAD) - developing a portfolio of assets targeting cancer 18 May 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an update on the company's pipeline and discusses the recent licensing …
Interviews / by Melissa Darmawan - 2 years ago Radiopharm Theranostics (ASX:RAD) - targeted cancer therapies 01 Apr 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari introduces the company, discussing the use of radiopharmaceuticals for cancer tr…
Company Presentations / by - 2 years ago Radiopharm Theranostics (ASX:RAD) Presentation, FNN Investor Event, February 2022 24 Feb 2022 - Radiopharm Theranostics Limited (ASX:RAD) CEO and Managing Director Riccardo Canevari provides an overview of the company, discussing the radiopharmaceutical space in…
